Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Rezolute, Inc. - Common Stock (NV) (NQ: RZLT )

4.610 -0.200 (-4.16%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Rezolute, Inc. - Common Stock (NV)

< Previous 1 2 3 4 5 Next >
Why Urban Outfitters Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Is Small-Cap Metabolic-Focused Rezolute Stock Trading Higher On Wednesday?
Rezolute announced topline results from the Phase 2 study of RZ402 for diabetic macular edema, showing significant improvements in macular edema and a favorable safety profile. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are worth checking out on Wednesday as we offer up all the latest news sending shares higher and lower this morning! 
Via InvestorPlace
RZLT Stock Earnings: Rezolute Misses EPS for Q3 2024
RZLT stock results show that Rezolute missed analyst estimates for earnings per share the third quarter of 2024. 
Via InvestorPlace
Rezolute Inc. (NASDAQ: RZLT) Climbs to New 52-Week High
Via Investor Brand Network
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update
From Rezolute, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Analyst Expectations for Rezolute's Future
Via Benzinga
Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting
From Rezolute, Inc.
Via GlobeNewswire
Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?
Discover three biotech stocks with explosive growth potential. Don't miss out on these great picks this year. 
Via InvestorPlace
CommScope Holding And 2 Other Stocks Under $3 Insiders Are Buying
The Dow Jones index closed higher by around 0.1% on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
Exposures US Equities
3 Stocks Insiders Are Buying That Analysts Love
Insiders are buying these stocks that analysts view as undervalued. Each has a potential catalyst in the works, and its shares could advance triple digits. 
Via MarketBeat
$17M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
The Dow Jones index closed higher by over 300 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
Exposures US Equities
$1.5M Bet On This Penny Stock? Check Out These 4 Stocks Under $5 Insiders Are Aggressively Buying
The Dow Jones index closed lower by around 0.2% on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
Exposures US Equities
Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)
Potential to more than double the addressable patient population living with hypoglycemia resulting from insulin receptor over-activation (tumor hyperinsulinism) 
From Rezolute, Inc.
Via GlobeNewswire
Lumen Technologies And 3 Other Stocks Under $3 Insiders Are Buying
The Dow Jones index closed lower by around 100 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
Exposures US Equities
Charles & Colvard And 3 Other Stocks Under $2 Insiders Are Buying
The Dow Jones index closed higher by around 0.1% on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
Exposures US Equities
Rezolute And 3 Other Penny Stocks Insiders Are Buying
The Dow Jones index closed lower by more than 60 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
Exposures US Equities
Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
From Rezolute, Inc.
Via GlobeNewswire
Why Aclarion Shares Are Trading Higher By Around 53%; Here Are 20 Stocks Moving Premarket
Shares of Aclarion, Inc. (NASDAQ: ACON) shares rose sharply in pre-market trading after the company was granted U.S. patent #11844601 for "MR SPECTROSCOPY SYSTEM FOR DIAGNOSING PAINFUL AND NON-PAINFUL... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)
Plans to report topline data mid-second quarter 2024 
From Rezolute, Inc.
Via GlobeNewswire
Stonegate Healthcare Partners Announces Black Friday Biotech Special Report For an "XBI-MAS"
Dallas, Texas--(Newsfile Corp. - November 24, 2023) - Stonegate Healthcare Partners highlights a unique opportunity in its report, "Black Friday... 
Via Newsfile
Rezolute to Participate in BTIG’s 3rd Annual Ophthalmology Day
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Reports First Quarter Fiscal 2024 Results
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism
PRIME eligibility granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital hyperinsulinism 
From Rezolute, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback